Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASH
Late-breaking final iDFS analysis from NATALEE investigating Kisqali® (ribociclib) in broad population of patients with stage II and III HR+/HER2-...